Biogen (XSWX:BIIB) Current Accrued Expense: CHF1,786 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:BIIB Biogen Inc XSWX:BIIB
77 GF Score
Price CHF173.46
GF Value CHF165.07
! 10 Warning Signs
View Full Analysis

What is Biogen Current Accrued Expense?

Biogen XSWX:BIIB 77 Current Accrued Expense is CHF1,786 Mil as of Jun. 2026. GuruFocus rates XSWX:BIIB with a GF Score™ of 77/100 and a GF Value™ of CHF165.07. The stock has 10 warning signs investors should review.

Biogen's Current Accrued Expense for the quarter that ended in Jun. 2026 was CHF1,786 Mil.

Biogen's quarterly Current Accrued Expense declined from Dec. 2025 (CHF1,934 Mil) to Mar. 2026 (CHF1,854 Mil) and declined from Mar. 2026 (CHF1,854 Mil) to Jun. 2026 (CHF1,786 Mil).

Biogen's annual Current Accrued Expense increased from Dec. 2023 (CHF1,979 Mil) to Dec. 2024 (CHF2,168 Mil) but then declined from Dec. 2024 (CHF2,168 Mil) to Dec. 2025 (CHF1,934 Mil).

Biogen Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Biogen's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogen Current Accrued Expense Chart

Biogen Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,017.08 1,284.58 1,979.10 2,168.28 1,933.92

Biogen Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,850.76 1,889.78 1,933.92 1,853.54 1,786.44
XSWX:BIIB
77GF Score
Biogen Inc XSWX:BIIB
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogen Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of CHF1,786 Mil mean?
Biogen (XSWX:BIIB) has a Current Accrued Expense of CHF1,786 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Biogen and its competitors.
Is Biogen's Current Accrued Expense too high?
Biogen's current Current Accrued Expense is CHF1,786 Mil. Overall, Biogen has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's Current Accrued Expense compare to OGN and AMRN?
Biogen's Current Accrued Expense of CHF1,786 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Drug Manufacturers company?
A good Current Accrued Expense depends on the Drug Manufacturers industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Biogen and its competitors. Biogen's current Current Accrued Expense is CHF1,786 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current Current Accrued Expense of CHF1,786 Mil. The stock's GF Value™ is CHF165.07, compared to a current price of CHF173.46 — trading 5.1% above its estimated fair value. The current Current Accrued Expense is CHF1,786 Mil. Biogen's overall GF Score™ is 77/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current Current Accrued Expense is CHF1,786 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogen (XSWX:BIIB) Overvalued in 2026?

Based on GuruFocus' analysis, Biogen stock appears to be overvalued. The current stock price of CHF173.46 is trading 5.1% above its estimated GF Value™ of CHF165.07.

Key valuation signals for XSWX:BIIB:

  • Current Accrued Expense: CHF1,786 Mil
  • GF Value™: CHF165.07 vs. price of CHF173.46 (5.1% above fair value)
  • GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogen Business Description

Address 225 Binney Street, Cambridge, MA, USA, 02142
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
77GF Score

Get the complete analysis for XSWX:BIIB

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF173.46
Price
CHF165.07
GF Value